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There is an increasing pressure to develop cost-effective strategies to mitigate persistently high levels of rehospital-
ization and premature mortality associated with chronic heart 
disease. Beyond pharmacological agents and devices, dis-
ease management programs are integral to applying flexible, 
guideline-based management, coordinating care, and provid-
ing individualized support.1,2 However, the evidence to sup-
port their application across the full spectrum of heart disease 
remains incomplete and fragmented. For example, although 
the overall evidence supporting short-term cardiac rehabilita-
tion3 and chronic heart failure (CHF) management4 programs 
is extensive and mostly favorable, there is a paucity of research 
to support programs designed to prevent progressive cardiac 
dysfunction in patients who survive an acute coronary syn-
drome5 or to optimize outcomes in those with atrial fibrilla-
tion (AF).6,7 Moreover, a diverse range of disease management 
techniques have been tested. Ideally, the same form of disease 
management program adapted to the individual patient pro-
file would be tested across a diverse range of cardiac patients 
receiving high levels of standard care to determine its overall 
potential to improve health outcomes in the real-world setting.
Editorial, see p 1836 
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In the absence of a single definitive trial, we conducted 3 
contiguous trials examining the benefits of the same model 
Background—We sought to determine the overall impact of a nurse-led, multidisciplinary home-based intervention (HBI) 
adapted to hospitalized patients with chronic forms of heart disease of varying types.
Methods and Results—Prospectively planned, combined, secondary analysis of 3 randomized trials (1226 patients) of HBI were 
compared with standard management. Hospitalized patients presenting with heart disease but not heart failure, atrial fibrillation 
but not heart failure, and heart failure, as well, were recruited. Overall, 612 and 614 patients, respectively, were allocated to 
a home visit 7 to 14 days postdischarge by a cardiac nurse with follow-up and multidisciplinary support according to clinical 
need or standard management. The primary outcome of days-alive and out-of-hospital was examined on an intention-to-
treat basis. During 1371 days (interquartile range, 1112–1605) of follow-up, 218 patients died and 17 917 days of hospital 
stay were recorded. In comparison with standard management, HBI patients achieved significantly prolonged event-free 
survival (90.1% [95% confidence interval, 88.2–92.0] versus 87.2% [95% confidence interval, 85.1–89.3] days-alive and out-
of-hospital; P=0.020). This reflected less all-cause mortality (adjusted hazard ratio, 0.67; 95% confidence interval, 0.50–0.88; 
P=0.005) and unplanned hospital stay (median, 0.22 [interquartile range, 0–1.3] versus 0.36 [0–2.1] days/100 days follow-up; 
P=0.011). Analyses of the differential impact of HBI on all-cause mortality showed significant interactions (characterized by 
U-shaped relationships) with age (P=0.005) and comorbidity (P=0.041); HBI was most effective for those aged 60 to 82 years 
(59%–65% of individual trial cohorts) and with a Charlson Comorbidity Index Score of 5 to 8 (36%–61%).
Conclusions—These data provide further support for the application of postdischarge HBI across the full spectrum of 
patients being hospitalized for chronic forms of heart disease.
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of care (nurse-led, multidisciplinary, home-based intervention 
[HBI]) to prevent secondary events in hospitalized patients 
spanning the continuum of heart disease. In each trial, we pos-
tulated that the benefits of HBI would transcend a patient’s 
specific cardiac needs and would be more responsive to their 
wider clinical and psychosocial needs with improvements in 
all-cause health outcomes. We now report on a prospectively 
planned, composite analysis of study outcomes from these 
trials. A priori, we postulated that, in the overall setting of 
chronic heart disease, HBI is superior to standard care in pre-
venting recurrent hospitalization and premature mortality on 
an all-cause basis in patients with any form of chronic heart 
disease.
Methods
Study Design and Patients
Baseline and outcome data were combined from 3 trials target-
ing hospitalized patients with: (1) a range of chronic heart disease 
states (most presented with acute coronary syndrome) but not CHF 
(n=611) enrolled in the Nurse-led Intervention for Less Chronic 
Heart Failure (NIL-CHF) Study8; (2) chronic AF but not CHF 
(n=335) enrolled in the Standard versus Atrial Fibrillation Specific 
Management Strategy (SAFETY) Trial9; and (3) CHF (n=280) 
enrolled in the Which Heart Failure Intervention Is Most Cost-
effective & Consumer Friendly in Reducing Heart Failure Hospital 
Care (WHICH?) Trial.10 All 3 trials were registered via www.anzctr.
org.au (12608000022369,12610000221055, and 12607000069459, 
respectively) and conducted with appropriate ethics approval.
Detailed descriptions of each study design5,11,12 and subse-
quent outcomes8–10 (including extended follow-up of the WHICH? 
Cohort)13 were published between 2011 and 2015. Each adhered 
to CONSORT guidelines for conducting pragmatic health ser-
vice interventions.14 Applying the same methods of recruitment, 
profiling, and follow-up, with only minor differences in clinical 
management specific to the target patient population, data were 
derived from 1226 patients recruited from 6 tertiary referral hospi-
tals across 5 Australian states with a combined follow-up of 4517 
person-years (see Table 1).
A blinded, computer-generated randomized protocol was imple-
mented by an independent data management team via telephone for 
each study with a predetermined, block randomization sequence for 
individual study sites. Stratification for reduced versus preserved 
ejection fraction in the WHICH? Trial of patients with CHF and nom-
inated rhythm versus rate control in the SAFETY Trial of patients 
with AF were applied. Overall, 612 and 614 patients were allocated 
to HBI and standard management, respectively.
Study Data
All patients were comprehensively profiled during their index 
admission by using the same framework of profiling and data 
entry. This included sociodemographic status, past medical history 
(including details specific to their primary reason for trial inclu-
sion), clinical profile, in-hospital management, and planned post-
discharge care.
Clinical Management
No restrictions on the level of standard management (other than no 
structured home visits) were applied. Treating physicians were rou-
tinely sent a copy of the hospital discharge summary and information 
about the trial and group allocation. Postdischarge, patients had unre-
stricted access to outpatient management via >50 specialist physi-
cians (predominantly cardiologists), routine follow-up provided by 
941 primary care physicians, subsidized pharmacological treatment, 
and referral to allied healthcare services when required. Common 
elements of the HBI were as follows: (1) a home visit 7 to 14 days 
posthospitalization conducted by a registered cardiac nurse with ter-
tiary qualifications; (2) comprehensive automated reports derived 
from baseline and home profiling providing treating physicians with 
recommendations to address any treatment or management deficits; 
(3) coordination of multidisciplinary follow-up; (4) telephone follow-
up by the cardiac nurse with both scheduled and patient-initiated con-
tacts; (5) a strong focus on the 6 months postindex hospitalization 
to address residual risk with reapplication of home visits if a patient 
experienced an unplanned hospitalization; and (6) structured review 
and generation of a comprehensive report and recommendations for 
optimal long-term management once active study management was 
discontinued. Table 215–20 summarizes the specific features of postdis-
charge management for the 3 studies.
End Points
Health outcomes were collected via electronic health records by per-
sonnel masked to group allocation. Subsequent adjudication of the 
type and nature of recurrent hospitalizations were determined by each 
study’s blinded end point committee. The primary end point for this 
composite analysis was event-free survival expressed as the propor-
tion of actual versus maximal unplanned days-alive (a combined 
total of 1 648 560 days) and out-of-hospital (DAOH). For example, 
a patient who experienced 10 days of unplanned hospitalization and 
died on day 700 of 730 possible days follow-up achieved 690 of 730 
DAOH (94.5% of maximal). The 2 components of this end point, all-
cause deaths and days of unplanned hospitalization, were also exam-
ined separately. Hospitalization data (episodes and related overnight 
hospital stay) were also examined on an all-cause, unplanned, and 
cardiovascular-specific basis.
Statistical Analysis
Profiling and outcome data from the 3 studies were pooled and 
analyzed using SPSS v22.0. Discrete variables were summarized 
by frequencies and percentages and continuous variables by means 
(standard deviation) and medians (interquartile range) where appro-
priate. Between-group comparisons of health outcomes (including 
the primary end point) were assessed by Mann-Whitney U test. All 
efficacy analyses were undertaken on an intention-to-treat basis and 
blinded to group allocation. Multivariate analyses used the baseline 
variables listed in Table 3.21,22 Survival data were used to generate 
Kaplan–Meier survival curves and group comparisons analyzed with 
the log-rank test. A Cox proportional hazards model was constructed 
to derive adjusted hazard ratios (HRs) for independent correlates of 
all-cause mortality using a backward, stepwise approach. All predic-
tors included in the Cox model were from baseline and were not time 
varying. We tested only for covariates of mortality, not management 
group, because covariates were from baseline, and random assignment 
to treatment group will ensure no systematic effects beyond chance. 
The assumption of proportional hazards was tested for the effect of 
treatment by using time-weighted score tests and the assumption was 
not rejected (P>0.05). Because of incomplete data for left ventricular 
ejection fraction (n=839) and cognitive function (n=1004), these 2 
variables were initially excluded and then added to the final iteration 
to determine their impact on the explanatory variables. Patient hos-
pital activity data (unplanned, all-cause, and cardiovascular related) 
were converted to the rate of hospitalizations and days of hospital 
stay per 100 days of follow-up. An exploration of the relative impact 
of HBI on being in the worst quintile of DAOH and experiencing a 
fatal event was conducted by including a condition×trial interaction 
in logistic regression models. We also explored the possibility that 
there was a differential intervention effect according to the age of 
the patient and their burden of disease (as measured by the Charlson 
Comorbidity Index Score23); both were treated as continuous vari-
ables and tested by including a condition×age and condition×age2 or 
condition×comorbidities and condition×comorbidities2 interaction 
terms in the regression models. Quadratic terms were included to 
allow the possibility that there was a U- or J-shaped pattern of inter-
ventional effect. If the quadratic term was not statistically significant, 
it was dropped.
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Table 1. Major Design Features of the NIL-CHF Study, SAFETY Trial, and WHICH? Trial
Inclusion Criteria Exclusion Criteria Indicative Cohort Profile Major Outcome Measures
NIL-CHF 
Study5,8
•  All elective and emergency 
patients admitted to the 
cardiology unit of a tertiary 
hospital with specialist 
cardiac services in Melbourne, 
Australia, between June 2008 
and July 2010.
•  All cardiac inpatients aged ≥ 
45 y were screened for study 
eligibility.
•  Patients must present with 
a cardiovascular diagnosis 
requiring active treatment.
•  Eligible patients must live 
within a 40-km radius of the 
hospital
•  Eligible patients must be 
English speaking.
•  Patients with a congenital 
condition, surgically 
repairable, or significant 
valve disease.
•  Patients with a terminal 
condition at the time of the 
index admission.
•  Cases of preexisting CHF 
arising from the index 
admission.
•  Randomly assigned 
patients were excluded 
from end point analyses 
if they experienced a 
CHF-related admission 
within 30 days of hospital 
discharge.
Mean age:
Female:
Live alone:
Obese:
Smoker:
Hypertension:
Type 2 diabetes 
mellitus:
Anemia
Renal Impairment:
Depressive symptoms:
Cognitive impairment:
Charlson Comorbidity 
Score:
Median (IQR) index  
stay, days
66 (11)
29%
39%
34%
18%
62%
26%
N/A
16%
24%
49%
4.7 (2.8)
4 (2–7)
Primary: De novo CHF-related 
hospitalization or all-cause mortality 
during 3- to 5-y follow-up.
Secondary: Rate of emergency, 
cardiovascular-related and all-
cause hospitalization, and days 
of hospital stay. Cardiac function 
from baseline to 3 y according to 5 
prespecified criteria consistent with 
expert guidelines:
•  No evidence of a cardiac 
abnormality
•  Systolic dysfunction
•  Diastolic dysfunction
•  A combination of systolic and 
diastolic dysfunction
•  Any other cardiac abnormality 
including left ventricular 
hypertrophy
Event-free survival from death or 
unplanned hospitalization.
SAFETY 
Trial9,12
•  Patient recruitment 
commenced on June 2, 
2010 from sites in Adelaide, 
Melbourne and Canberra, 
Australia
•  Patients admitted to the 
cardiac units of participating 
hospitals were eligible to 
participate if they had a 
diagnosis of chronic AF.
•  Eligible patients were living 
independently within a 40-km 
radius of the hospital and 
were able to provide informed 
consent.
•  Patients with a primary 
diagnosis of valvular 
heart disease, scheduled 
catheter ablation 
procedure, preexisting 
diagnosis of HF, alcohol-
induced AF, or a terminal 
condition/malignancy 
requiring palliative care.
Mean age:
Female:
Live alone:
Obese:
Smoker:
Hypertension:
Type 2 diabetes 
mellitus:
Anemia:
Renal impairment:
Depressive symptoms:
Cognitive impairment:
Charlson Comorbidity 
Score:
Median (IQR) index stay, 
days
72 (11)
48%
39%
43%
14%
72%
29%
14%
35%
36%
65%
4.9 (2.6)
3 (1–5)
Primary: Days-alive and out-
of-hospital (unplanned) during 
minimum 2 y follow-up.
Secondary: All-cause mortality. 
Rate of emergency, cardiovascular-
related and all-cause 
hospitalization, and days of related 
hospital stay.
WHICH? 
Trial10,11
•  Patient recruitment 
commenced on June 1, 
2008 from sites in Adelaide, 
Brisbane and Sydney, Australia
•  Patients admitted to the 
cardiac units of participating 
hospitals were eligible to 
participate if they were aged 
≥ 18 y, discharged to home 
with a cardiologist-confirmed 
diagnosis of CHF (based on 
echocardiography), persistent 
moderate to severe symptoms 
(NYHA Class II–IV) and a recent 
history of ≥1 admission for 
acute HF.
•  Patients who lived outside 
a 30-km radius of the 
hospital were excluded.
•  Patients who were unable 
to perform informed 
consent, and who were 
non-English speaking were 
excluded.
•  Patients were excluded 
if they had a terminal 
condition.
Mean age:
Female:
Live alone:
Obese:
Smoker:
Hypertension:
Type 2 diabetes 
mellitus:
Anemia:
Renal impairment:
Depressive symptoms:
Cognitive impairment:
Charlson Comorbidity 
Score:
Median (IQR) index stay, 
days
71(14)
27%
55%
N/A
69%
63%
39%
39%
61%
35%
40%
6.4 (2.4)
7 (4–11)
Primary: Unplanned hospitalization 
or mortality during 12–18 mo of 
follow-up (dichotomous event-free 
survival and expressed as days-
alive and out-of-hospital).
Secondary: Rate of emergency, 
cardiovascular-related, HF-related 
and all-cause hospitalization, and 
days of related hospital stay.
Longer-term survival and health 
care activity during minimum 3-y 
follow-up.
AF indicates atrial fibrillation; CHF, chronic heart failure; HF, heart failure; and NYHA, New York Heart Association.
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Table 2. Characteristics of Clinical Management in the NIL-CHF Study, SAFETY Trial, and WHICH? Trial
Study Intervention Standard Care
NIL-CHF Study5,8 •  Management was explicitly guided by expert guidelines for the secondary 
prevention of heart disease.15
•  Short-term cardiac rehabilitation was offered to patients discharged from 
hospital with an ACS.
•  Comprehensive home visit at 7–14 days after index hospital discharge 
supplemented by comprehensive clinical profiling (including echocardiography 
and functional testing) at a nurse-led clinic at 30–35 days postdischarge.
•  Based on initial profiling, an individualized management plan based on the 
Green Amber and Red Delineation of rIsk And Need (GARDIAN) tool16 was used 
to generate an initial report and recommendations for clinical support and 
management and sent to the patient’s primary care and specialist physician. A 
cardiac nurse then implemented that plan (with a strong focus on preventing 
progressive cardiac dysfunction) via a combination of repeat home visits, 
telephone follow-up, and multidisciplinary support.
•  At 18 mo and 36 mo, a repeat visit to the nurse-led clinic for follow-up 
clinical profiling and review of management goals relative to expert secondary 
prevention guidelines15 was conducted.
•  Follow-up by the cardiac nurse with multidisciplinary support applied between 
18 and 36 mo.
•  A final report and recommendations for longer-term clinical support and management 
was sent to the patient’s primary care and specialist physician at 36 mo.
•  Management was broadly guided by expert 
guidelines for the secondary prevention of heart 
disease.15
•  Short-term cardiac rehabilitation was offered to 
patients discharged from hospital with an ACS.
•  Vicarious management applied by the cardiologists 
based at the Heart Center of a specialist tertiary 
referral hospital and the patient’s primary care 
physician.
•  Clinical profiling (with structured reports of findings 
sent to the patient’s healthcare team) conducted 
at 30–35 days and 36 mo postindex hospital 
discharge.
SAFETY Trial9,12 •  Management was explicitly guided by expert guidelines for the management of 
chronic forms of AF.17
•  Comprehensive home visit at 7–14 days postdischarge supplemented by 24-h 
ECG Holter monitoring and detailed profiling for thromboembolic events and 
progressive cardiac dysfunction before the home visit.18
•  Based on initial profiling, an individualized management plan based on the 
GARDIAN tool16 was used to generate an initial report and recommendations 
for clinical support and management and sent to the patient’s primary care 
physician and cardiologist. A cardiac nurse then implemented that plan (with 
a strong focus on optimal AF management) via a combination of repeat home 
visits, telephone follow-up, and multidisciplinary support.
•  Repeat 24-h ECG Holter monitoring applied at 12 mo.
•  At 12 and 24 mo, a visit to a nurse-led clinic for follow-up clinical profiling and 
review of management goals relative to expert guidelines for AF17 and secondary 
cardiac prevention15 was conducted.
•  Follow-up by the cardiac nurse with multidisciplinary support applied between 
12 and 24 mo.
•  A final report and recommendations for longer-term clinical support and 
management for optimal AF was sent to the patient’s primary care and 
cardiologist at 24 mo.
•  Management was broadly guided by expert 
guidelines for the management of AF.17
•  Vicarious management applied by the patient’s 
cardiologist and primary care physician.
•  Comparative 24-h ECG Holter monitoring 
conducted at 12 mo.
•  Clinical profiling (with structured reports of findings 
sent to the patient’s healthcare team) conducted at 
12 and 24 mo postindex hospital discharge.
WHICH? Trial10,11 •  Management was explicitly guided by expert guidelines for the management of 
CHF.19,20
•  Comprehensive home visit at 7–14 days postdischarge supplemented by 
detailed profiling of multimorbidity (including anemia, renal dysfunction, 
depression, and cognitive impairment) and ability to self-care before the home 
visit.
•  Based on initial profiling, an individualized management plan was used to 
generate an initial report and recommendations for clinical support and 
management and sent to the patient’s primary care physician and cardiologist. 
A HF nurse then implemented that plan (with a strong focus on optimal HF 
management) via a combination of repeat home visits, telephone follow-up, and 
multidisciplinary support (including specialist HF clinic visits) up to 18 mo.
•  At 12–18 mo, a home visit for follow-up clinical profiling and review of 
management goals relative to expert guidelines for CHF management19,20 was 
conducted.
•  A final report and recommendations for longer-term clinical support and 
management for optimal CHF management was sent to the patient’s primary 
care physician and cardiologist at 12–18 mo.
•  Management was explicitly guided by expert 
guidelines for the management of CHF.19,20
•  The same principles and structure of management 
as HBI was applied via a specialist, outpatient HF 
clinic at each participating hospital.
•  No home visits were applied.
ACS indicates acute coronary syndrome; AF, atrial fibrillation; CHF, chronic heart failure; HBI, home-based intervention; and HF, heart failure.
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Table 3. Baseline Characteristics According to Group Assignment and Sex (n=1226)
Home-Based Intervention Standard Management
Men (n=394) Women (n=218) Men (n=415) Women (n=199)
Sociodemographic profile
  Age, y 67 (12) 72 (11) 68 (12) 71 (12)
  Living alone* 152/393 (39%) 111/218 (51%) 147/412 (36%) 111/198 (56%)
  <12 y education* 209/391 (54%) 134/217 (62%) 223/411 (54%) 128/197 (65%)
Risk factors*
  Obese (body mass index ≥30 kg/m2) 128/364 (35%) 80/199 (40%) 128/369 (35%) 65/173 (38%)
  Abdominal obesity 239/337 (71%) 140/168 (83%) 233/317 (74%) 121/149 (81%)
  Hypertension (BP ≥130/80 mm Hg) 214/379 (57%) 124/210 (59%) 222/384 (58%) 105/185 (57%)
  Meeting exercise guidelines 173/392 (44%) 75/218 (34%) 172/408 (42%) 60/195 (31%)
  Current smoker 87/393 (22%) 19/218 (9%) 73/412 (18%) 31/195 (16%)
  High-risk alcohol use 88/387 (23%) 14/214 (7%) 91/408 (22%) 12/194 (6%)
  Total cholesterol ≥4 mmol/L 125/319 (39%) 110/173 (64%) 131/312 (42%) 87/152 (57%)
  High-density lipoprotein ≤1 mmol/L 174/302 (58%) 39/160 (24%) 162/299 (54%) 42/143 (29%)
  Low-density lipoprotein ≥2 mmol/L 136/273 (50%) 85/152 (56%) 137/272 (50%) 80/138 (58%)
Clinical profile
  Systolic BP, mm Hg 130 (20) 133 (23) 131 (21) 130 (21)
  Diastolic BP, mm Hg 74 (14) 73 (14) 75 (14) 70 (13)
  Heart rate, beats/min* 81 (27) 86 (28) 80 (23) 87 (30)
  Left ventricular ejection fraction* 50 (17) 56 (14) 53 (17) 60 (15)
  Type 2 diabetes mellitus 123 (31%) 57 (26%) 133 (32%) 53 (27%)
  Renal dysfunction (eGFR<60mL·min–1·1.73m–2)* 100/383 (26%) 78/210 (37%) 122/388 (31%) 69/189 (37%)
  Anemia (sex-specific)* 143/380 (38%) 83/210 (40%) 147/386 (38%) 61/190 (32%)
  Charlson Comorbidity Index Score 5.0 (2.9) 5.2 (2.5) 5.1 (2.7) 5.0 (2.5)
  Depressive symptoms* 155/390 (40%) 89/218 (41%) 142/407 (35%) 77/195 (40%)
  Mild cognitive impairment* 166/330 (50%) 85/176 (48%) 180/342 (53%) 87/156 (56%)
In-hospital management
  Median length of stay 4.5 (2.0–8.0) 4.0 (2.0–8.0) 4.0 (2.0–8.0) 4.0 (2.0–8.0)
  Median days in specialist/intensive care 3.0 (0–6.0) 2.0 (0–4.3) 2.0 (0–6.0) 2·0 (0–5.0)
  Coronary revascularization 96 (24%) 25 (12%) 110 (27%) 23 (12%)
Primary discharge diagnosis
  Acute coronary syndrome 81 (21%) 32 (15%) 84 (20%) 31 (16%)
  Acute heart failure 72 (18%) 37 (17%) 65 (16%) 30 (15%)
  Stable coronary artery disease 63 (16%) 19 (9%) 57 (14%) 20 (10%)
  Atrial Fibrillation 59 (15%) 56 (26%) 66 (16%) 60 (30%)
Discharge pharmacotherapy
  Lipid-lowering agent 291 (74%) 143 (66%) 302 (73%) 130 (65%)
  Antiplatelet therapy 282 (72%) 142 (65%) 290 (70%) 123 (62%)
  Angiotensin blockade 272 (69%) 152 (70%) 303 (73%) 128 (64%)
  β-Blocker 232 (59%) 108 (50%) 240 (58%) 98 (49%)
  Diuretic 145 (37%) 101 (46%) 148 (36%) 89 (45%)
  Nitrate therapy 135 (34%) 65 (30%) 140 (34%) 62 (31%)
  Antiarrhythmic agent 135 (34%) 87 (40%) 131 (32%) 104 (52%)
  Anticoagulant 102 (26%) 75 (34%) 132 (32%) 63 (32%)
Data are presented as mean (SD), median (IQR), or number of patients (%). Depressive symptoms determined by positive response to a 2-item Arroll tool21 and mild 
cognitive impairment score is <26 on the Montreal Cognitive Assessment tool.22 BP indicates blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile 
range; and SD, standard deviation.
*Data not available for all randomly assigned patients.
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Results
Cohort Profile
Between June 1, 2008 and March 31, 2011, 1226 of 10 382 
cardiac inpatients at participating hospitals were eligible for 
study entry, randomly assigned to a study group, and followed 
for study outcomes (Figure 1). Median follow-up of 1371 days 
(interquartile range, 1112–1605) across the 3 studies was com-
pleted by March 31, 2014. Reflective of the increasing severity 
of disease across this family of trials, multimorbidity, as mea-
sured by the mean (age-adjusted) Charlson Comorbidity Index 
Score23 was 4.7, 4.9, and 6.2 in the NIL-CHF, SAFETY, and 
WHICH? Trial cohorts. The HBI and standard management 
groups were well matched for sociodemographic characteristics 
and clinical profile according to sex (Table 3). The most com-
mon primary discharge diagnoses were AF (20%), acute coro-
nary syndrome (19%), and acute HF (17%); the majority being 
admitted for a cardiovascular-related diagnosis (Figure 2). 
Women comprised 34% of patients and were on average 4 years 
older than men. Overall, patients had high levels of antecedent 
risk for secondary events and noncardiovascular multimorbid-
ity complicating their clinical management. Pharmacological 
management included appropriately prescribed levels of anti-
platelet/coagulant agents, lipid-lowering, angiotensin blockade, 
β-blockade, diuretics, and antiarrhythmic agents (Table 3).
Primary End Point: Days Alive and Out of Hospital
Based on favorable outcome data with respect to both survival 
and hospital stay (see Survival Profile and Hospitalizations 
below), the HBI group accumulated more DAOH (737 852 of 
a maximal 821 707 days) than those allocated to standard man-
agement (723 527 of 826 853 days). Specifically, HBI patients 
experienced a mean of 1210 (standard deviation, 463) DAOH 
equating to 90.1% (95% confidence interval [CI], 88.2–92.0) 
days event free. In comparison, standard management patients 
experienced 1184 (standard deviation, 494) DAOH equating 
to 87.2% (95% CI, 85.1–89.3) days event free (P=0.02).
Survival Profile
Overall, 94 of 612 (15%) patients allocated to HBI died 
in comparison with 124 of 614 (20%) patients allocated 
to standard management. HBI was associated with signifi-
cantly prolonged survival (unadjusted HR, 0.75; 95% CI, 
0.57–0.98; P=0.032; Figure 3). The effect was even stronger 
(HR, 0.67; 95% CI, 0.50–0.88; P=0.005) after adjusting for 
age (HR, 1.04; 95% CI, 1.02–1.05 per year; P<0.001); age-
adjusted Charlson Comorbidity Index Score (HR, 1.22; 95% 
CI, 1.16–1.28 per unit score; P<0.001), AF (HR, 2.02; 95% 
CI, 1.46–2.79; P=0.006), being treated for hypertension (HR, 
0.67; 95% CI, 0.51–0.88; P=0.004), prescribed a diuretic 
(HR, 2.96; 95% CI, 2.12–4.13; P<0.001), and index length 
of stay (HR, 1.03; 95% CI, 1.03–1.04 per day; P<0.001). 
When added in a separate model, left ventricular ejection 
fraction (HR, 0.97; 95% CI, 0.96–0.98 per unit increment) 
was also correlated with survival without substantially alter-
ing the original model.
Hospitalizations
The HBI group accumulated 7469 days of hospital stay from 
1336 unplanned hospitalizations in comparison with 10 448 
days from 1412 unplanned hospitalizations in the standard 
management group. Adjusting for duration of follow-up, the 
HBI group accumulated significantly fewer cardiovascular 
admissions and accumulated significantly fewer days of hospi-
tal stay across all 3 categories of hospital activity (unplanned, 
cardiovascular related, and total all-cause; see Table 4).
Figure 1. Combined study flow-chart.
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Differential Impact of HBI
For the worst quintile of DAOH (greatest number of days 
lost to hospital stay and death), the omnibus test of the 
trial×condition interaction did not reach statistical signifi-
cance (P=0.055). There were no significant differences in the 
intervention effect between the WHICH? and SAFETY tri-
als (P=0.928), and the intervention effects were comparable 
(odds ratio, 0.50; 95% CI, 0.28–0.88 in SAFETY and odds 
ratio, 0.49; 95% CI, 0.30–0.78 in WHICH?). However, there 
was a difference between the NIL-CHF Study and WHICH? 
(P=0.026) and the SAFETY Trial (P=0.049), and the interven-
tion effect was smaller overall in NIL-CHF (odds ratio, 1.12; 
95% CI, 0.64–1.97).
For all-cause mortality, the omnibus test of the 
trial×condition interaction was not statistically significant 
(P=0.208). Examining the specific contrasts between trials 
also revealed no statistically significant differences (WHICH? 
versus SAFETY, P=0.946; WHICH? versus NIL-CHF, 
P=0.085; SAFETY versus NIL-CHF, P=0.168). For lowest 
quintile of DAOH, the condition×age2 interaction was signifi-
cant (P=0.045), revealing a U-shaped relationship (see Figure 
4). HBI had a significant, beneficial effect for adults who were 
59 to 81 years old; this age range was predominant in WHICH? 
(58%), SAFETY (62%), and NIL-CHF (64%). For extent of 
comorbidity, the direction of the effect was the same U-shaped 
relation as for age. However, the condition×comorbidities2 
Figure 2. Primary cause of index hospitalization.
Figure 3. Kaplan–Meier (all-cause) survival 
plots. Nurse-led, multidisciplinary home-based 
intervention (518 censored observations) and 
standard management (490 censored observations). 
CI indicates confidence interval.
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interaction did not reach statistical significance (P=0.083). 
For all-cause mortality, the condition×age2 interaction was 
significant (P=0.005), revealing a U-shaped relationship. HBI 
had a significant, beneficial effect for adults who were 60 
to 82 years old, an age range also predominant in WHICH? 
(59%), SAFETY (63%), and NIL-CHF (65%). For extent of 
comorbidity, the condition×comorbidities2 interaction was 
also significant (P=0.041) and also displayed a U-shaped 
relationship. HBI had a significant, beneficial effect when the 
Charlson Comorbidity Index Score ranged from 5 to 8. This 
range was predominant in WHICH? (61%) and was common 
in SAFETY (45%) and NIL-CHF (36%).
Discussion
We combined outcome data from 3 closely related trials to 
examine the impact of HBI delivered by cardiac nurses with 
multidisciplinary support across the spectrum of heart disease. 
Historically, this model of care is reserved for those with CHF. 
However, as postulated, our composite findings suggest that 
HBI consistently prolongs DAOH in comparison with stan-
dard management across the full spectrum of chronic heart 
disease. DAOH represents a realistic and patient-focused out-
come because it does not rely on a single event, but rather 
reflects the entirety of the patient’s journey in terms of major 
outcomes.24 Moreover, it has particular relevance to interven-
tions seeking to prolong life while avoiding recurrent and 
often costly rehospitalization. Accordingly, positive find-
ings were derived from a significant reduction in unplanned 
hospital stay and prolonged survival during study follow-up. 
Absolute differences between groups were clinically compel-
ling. These positive differences were monitored over 2 to 5 
years follow-up in contrast to the frequent reporting of short-
term outcomes in those exposed to a secondary prevention 
program.3,4 For all-cause mortality, the number needed to treat 
to avert 1 additional death via the application of HBI was 21 
patients. At the same time, HBI was associated with close to 
600 fewer days of hospital stay per 100 patients. Overall, these 
unique data provide a strong case for extending the application 
of this model of care more widely to those hospitalized with 
any form of chronic heart disease.
The benefits of home-based models of care, with their abil-
ity to improve the contextual profiling of affected patients to 
strengthen factors shown to improve health outcomes are now 
well described.8–10 Benefits include addressing often unknown 
issues such as cognitive impairment and clinical instability via 
an individualized, case management approach and improving 
self-care behaviors. Accordingly, across the 3 trials, there was 
evidence (albeit not definitive) of greater levels of healthcare 
engagement, more patient-initiated contacts, greater preserva-
tion of cardiac function through better blood pressure control, 
and more proactive uptitration of gold-standard therapies.8–10 
The model of care applied in this instance was initially devel-
oped and successfully applied25 in patients with a broad range 
of chronic disease states before being specifically adapted 
for those with CHF; the subsequent trial report was the first 
to demonstrate both prolonged survival and reduced risk of 
recurrent hospitalization in this patient population.26 Since 
then, the literature has consistently demonstrated that an in-
person, multidisciplinary approach is superior to other modes 
of management (including remote management strategies) to 
improve health outcomes in CHF, and this is likely to be the 
case for all forms of chronic heart disease.2,4,15,17,19 Based on 
the totality of evidence, expert guidelines have recommended 
the application of multidisciplinary, face-to-face programs of 
management for those hospitalized with CHF,20 resulting in 
a global network of such programs. However, there has been 
a paucity of research and evidence to demonstrate that such 
an approach is beneficial more widely across the spectrum of 
chronic heart disease. These data, therefore, address an impor-
tant gap in the literature and evidence base.
Beyond questioning the relevance of data derived from 
Australia (characterized by high standards of subsidized 
health care), it is worth considering whether a blanket 
approach to applying HBI is truly warranted. For example, in 
the recent Young@Heart Study,27 applying HBI in a wealthier 
cohort of cardiac patients with greater access to a specialist 
Cardiologist, men but not women appeared to benefit from 
Table 4. Group Comparison of Hospital Outcomes
Home-Based  
Intervention (n=612)
Standard  
Management (n=614)
Median (IQR) Rate per  
100 Days Follow-up P Value
Total follow-up (days) 747 827 737 090
Median (IQR) follow-up, days 1321 (922–1571) 1295 (868–1587) 0.568
Unplanned admissions, days of stay 1336 (7649) 1412 (10448)
  Median (IQR) admissions per patient 1 (0–3) 1 (0–3) 0.08 (0–0.32) vs 0.12 (0–0.35) 0.083
  Median (IQR) stay (days) per patient 3 (0–14) 4 (0–18) 0.22 (0–1.33) vs 0.36 (0–2.10) 0.011
Cardiovascular admissions, days of stay 735 (3334) 842 (4488)
  Median (IQR) admissions per patient 0 (0–2) 1 (0–3) 0 (0–0.16) vs 0.07 (0–0.19) 0.047
  Median (IQR) stay (days) per patient 0 (0–6) 1 (0–7) 0 (0–0.55) vs 0.11 (0–0.76) 0.039
All admissions, days of stay 1868 (9975) 2017 (13563)
  Median (IQR) admissions per patient 2 (1–4) 2 (1–5) 0.15 (0.05–0.42) vs 0.18 (0.06–0.52) 0.117
  Median (IQR) stay (days) per patient 6 (1–20) 7 (1–25) 0.49 (0.07–2.10) vs 0.67 (0.11–3.10) 0.017
IQR indicates interquartile range.
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HBI; the latter potentially attributable to suboptimal applica-
tion of HBI at 1 study site.27 Beyond health system factors, 
the relative impact of HBI will undoubtedly vary according to 
clinical acuity and risk of premature mortality and recurrent 
hospital stay. Exploratory analyses of the interaction between 
HBI and a patient’s age and comorbidity clearly showed a 
U-shaped response with respect to DAOH and survival alone, 
those at either end of the spectrum demonstrating an increased 
propensity to have more events when exposed to HBI. The 
potential to identify who benefits most from HBI and there-
fore to apply it on a more selective basis should not, however, 
detract from the overall benefits observed by this compos-
ite analysis; in particular, when one considers the unique 
advantage of HBI in being patient centered and detecting 
otherwise unknown clinical instability.4,28 The Green Amber 
Red Delineation of Risk and Need (GARDIAN) tool16 was 
designed to achieve the former and is being used to guide 
the intensity of disease management according to the level 
of need in current trials of HBI in the setting of CHF. It is 
certainly possible that high levels of standard management 
alone, including traditional outpatient care, deliver the best 
health outcomes in younger patients with less complex clini-
cal needs. Alternatively, the danger of not transitioning to a 
potentially more effective HBI over time is tempered by the 
natural history of heart disease toward more progressive, mul-
tiorgan disease and poor health outcomes in the long term.8,29 
With an increasingly ageing cardiac patient population in 
whom multimorbidity and rehospitalizations are becoming 
more common,30 our positive findings with respect to HBI, 
as a reflection of the overall benefits of applying successful 
Figure 4. Interaction between age and Charlson Comorbidity Score and impact of HBI on the risk of being in the worst quintile of DAOH 
(A and B) or dying (C and D). CBI indicates clinic-based intervention (standard management); CI, confidence interval; DAOH, days-alive 
and out-of-hospital; and HBI, home-based intervention.
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programs involving a home-based31 or transitional care32 
approach to chronic heart disease management, are likely to 
become more clinically relevant over time.
Beyond previously identified trial limitations, includ-
ing nonblinding of patients and health workers, a number of 
specific issues require comment. First, despite the purposeful 
nature of our program of research and efforts to standardize 
trial methodology,14 there were potentially important differ-
ences in the application of clinical management in each trial. 
One trial (the NIL-CHF Study)8 was conducted in a single ter-
tiary center. The applicability of our findings (both negative 
and positive) from studies conducted within the Australian 
healthcare system requires careful consideration in terms of 
their generalizability. Nevertheless, our analyses of who ben-
efits most from HBI remain ongoing and we are yet to under-
take economic analyses to determine whether there is a cost 
threshold at which HBI might be applied. Finally, our com-
posite findings are also yet to be tested via a single appropri-
ately powered, prospective study.
In conclusion, across 3 contiguous clinical trials applying 
the same form of nurse-led, multidisciplinary, HBI adapted to 
the target patient population, this model of care was associated 
with more DAOH than standard management. These data sup-
port the wider application of HBI to optimize the immediate 
and longer-term postdischarge management of patients with a 
broad spectrum of heart disease states.
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CLINICAL PERSPECTIvE
These data have important clinical implications for the application of disease management across the full spectrum of heart 
disease to prolong survival without provoking the competing risk of recurrent hospitalization. In combining 3 contiguous 
trials of the same form of management adapted to clinical profile (from younger individuals surviving an acute coronary 
event to older individuals hospitalized with more advanced forms of atrial fibrillation and chronic heart failure), we were 
able to tackle an important gap in the evidence base. Overall, we demonstrated that, in comparison with high levels of stan-
dard management, a nurse-led, multidisciplinary, home-based intervention was associated with both prolonged survival and 
reduced hospital stay over the longer term. Given that in clinical practice disease management programs are typically applied 
according to a single cardiac diagnosis (most notably chronic heart failure), overall, these data support the wider applica-
tion of this approach to any patient discharged home from the hospital with a form of chronic heart disease; particularly in 
older individuals with multimorbidity. On this basis, there is scope to extend preexisting health services applying this kind 
of approach to the full spectrum of heart disease on a cost-effective basis. This would involve modifications in screening and 
referral protocols (to identify eligible patients), more health resources to accommodate an increased case load, and critical 
adjustments to patient profiling and needs assessments to adapt this strategy on an individual basis.
